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Despite advances in resuscitation medicine, including
target temperature management as part of post-
cardiac arrest care, many patients will have a poor
neurological outcome, most often resulting in death.
It is a commonly held belief that the ability to
prognosticate outcome at an early stage after cardiac
arrest would allow subsequent health care delivery to
be tailored to individual patients. However, currently
available predictive methods and biomarkers lack
sufficient accuracy and therefore cannot be generally
recommended in clinical practice. MicroRNAs have
recently emerged as potential biomarkers of
cardiovascular diseases. While the biomarker value of
microRNAs for myocardial infarction or heart failure
has been extensively studied, less attention has been
devoted to their prognostic value after cardiac arrest.
This review highlights the recent discoveries suggesting
that microRNAs may be useful both to predict outcome
and to treat patients after cardiac arrest.tention and, until recently, was totally neglected.Introduction
Although half of the patients resuscitated from cardiac
arrest survive without major neurological sequelae, the
other half die and some other survivors have severe
neurological impairment. This is despite the widespread
use of therapeutic hypothermia and its potential neuro-
protective effects. Early outcome prognostication of pa-
tients resuscitated from cardiac arrest is challenging,
mostly due to the paucity of accurate tools. The imple-
mentation of mild induced hypothermia has complicated
matters further because the metabolism of sedatives is* Correspondence: yvan.devaux@crp-sante.lu
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found prognostication [1]. Until recently, clinical neuro-
logical examination and neurophysiological tests performed
several days after the arrest were the best indicators of
outcome [2,3]. The use of circulating biomarkers such as
neuron-specific enolase (NSE) improves outcome predic-
tion on a group basis and has been recommended in clin-
ical practice [4,5]. However, the discriminative ability of
these tests is sub-optimal in individual patients and man-
agement of individuals could potentially benefit from new
biomarkers.
Discovered in 2001 in Caenorhabditis elegans [6-8],
microRNAs (miRNAs) have attracted great interest in
the scientific community. The discovery of their pres-
ence and stability in the bloodstream [9,10] revealed
their potential as novel disease biomarkers. Multiple
groups have addressed the utility of circulating miRNAs
as biomarkers of cardiovascular diseases. The vast ma-
jority of studies focused on myocardial infarction and
heart failure. However, the potential of miRNAs to be
used as biomarkers of cardiac arrest has received less at-
In this article, we first review the current knowledge
on available biomarkers used to predict outcome after
cardiac arrest. Then, we discuss why it is critical to identify
new biomarkers, and how these new tools may enable im-
provements in health care and outcome of patients after
cardiac arrest. Finally, we present recent data suggesting
that miRNAs might be useful biomarkers and therapeutic
targets in this setting.Current biomarkers: limitations
In order to predict outcome of patients with post-anoxic
coma after circulatory arrest, biomarkers of neuronal
damage have been extensively studied. Creatine phospho-
kinase brain-brain (CK-BB), NSE and the astroglial protein
S100 calcium binding protein B (S100B) [11-14] have been
evaluated in cerebrospinal fluid and blood of cardiac arrest. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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levels of S100B and bispectral index monitoring accurately
predicts outcome after cardiac arrest [15]. For a systematic
review of the existing literature on biomarkers of cardiac
arrest, see [16,17].
The cutoff values of CK-BB and S100B required to ob-
tain sufficient specificity (and therefore sufficiently low
false positive rates) are substantially elevated. Conse-
quently, these biomarkers have low sensitivity, and are
of limited prognostic value.
Although NSE was identified in the late 1980s as a po-
tential marker of neurological outcome after cardiac ar-
rest [18], its clinical utility is still a subject of debate.
NSE is an isoenzyme of the glycolytic enzyme enolase
(2-phospho-D-glycerate hydrolase) and is mostly of neur-
onal and neuroendocrine origin. Its levels are elevated
after ischemic stroke, intracerebral hemorrhage, and trau-
matic and ischemic brain injury, rising just hours after
neuronal damage. These properties make NSE a potential
useful biomarker for neurologic outcome after cerebral in-
jury. The 2006 American Academy of Neurology guide-
lines on prediction of outcome in comatose survivors after
cardiopulmonary resuscitation advocated the use of NSE
as a biomarker to estimate neurologic outcome with a cut-
off value of >33 μg/L, which provided a false positive rate
of 0% (95% confidence interval 0 to 3%) [3,19]. However,
more recent studies do not support this guideline. Grubb
and colleagues [20] found a NSE cutoff value of >71.0 μg/
L 24 to 48 hours after cardiopulmonary resuscitation re-
sulted in a false positive rate of 0% (95% confidence inter-
val 0 to 43%) and a sensitivity of 14%. Other studies
showed cutoff values of 30 to 80 μg/L for poor neurologic
outcome and death [21,22]. Krumnikl and colleagues [23]
published a case report of a patient with good neurologic
outcome after a period of extended in-hospital cardio-
pulmonary resuscitation with a highest NSE value of
116.8 μg/L. Interestingly, hypothermia may affect serum
levels of NSE. Tiainen and colleagues [24] found that the
cutoff value of NSE, 48 hours after cardiopulmonary re-
suscitation and target temperature management, needed
to be two to three times higher compared with patients
not undergoing mild induced hypothermia (>25 versus
8.8 μg/L). Steffen and colleagues [25] also found higher
cutoff values after hypothermia (NSE 78.9 versus 26.9 μg/
L). In contrast, Wolff and colleagues [26] reported lower
cutoff values after hypothermia. In addition, there is
presently a lack of standardization of the measure-
ments of NSE. Several available laboratory tests show
variability of up to 40% between NSE values on the
same samples [27].
Interpreting data from biomarker studies is confounded
by differences in study design, inclusion/exclusion criteria
of patients, duration of treatment, time of sampling and
laboratory evaluation, as well as differences in evaluatedendpoints of treatment, making it difficult to compare
studies in a systematic review or a meta-analysis in a
meaningful way. Other more recently described bio-
markers such as procalcitonin [28-30], glial fibrillary acidic
protein [31], heparin binding protein [32] and brain-
derived natriuretic factor [33] face the same methodo-
logical issues and further large scale studies with an
accurate methodology are warranted.
Therefore, there is an urgent need for identifying novel
biomarkers that can guide patient management at an
early stage after cardiac arrest.
How will new biomarkers allow for patient-
oriented treatment and improvement of outcome?
Patients who remain unconscious following an out-of-
hospital cardiac arrest despite the return of spontaneous
circulation utilize considerable health care resources
during the first days of admission to the hospital. Pa-
tients often require immediate coronary intervention to
establish revascularization followed by mechanical venti-
lation in intensive care where they are treated with mild
induced hypothermia, frequently requiring sedation and
muscle paralysis. Cardiogenic shock and multiple organ
failure may further complicate the clinical course of
some survivors, necessitating high dose inotropic drugs,
vasopressors, renal replacement therapy, intra-aortic bal-
loon pumps, mechanical assist devices or extra-corporeal
membrane oxygenation [34,35]. Despite early aggressive
therapy, many of these patients will not survive due to ir-
reversible cerebral damage caused by the initial insult.
New biomarkers may be very valuable if they have suf-
ficient prognostic power when measured early after car-
diac arrest. Health care resources may then be applied to
patients who are most likely to benefit and futile care for
those patients with irreversible severe cerebral damage
can be avoided. Furthermore, patients’ relatives, who
often experience long delays before receiving reliable in-
formation about prognosis, may be informed and guided
early.
Emerging biomarkers: microRNAs
miRNAs are short (around 21 nucleotides) non-protein-
coding RNA molecules that are evolutionarily conserved
and ubiquitously expressed, albeit with a degree of tissue
specificity. Since the first version of The miRBase Se-
quence Database [36] in December 2002, the number of
known miRNAs has continued to grow. To date, as
many as 30,424 mature miRNAs have been characterized
in 206 species, with 2,578 in humans (release 20 June
2013).
Although miRNAs do not encode proteins, their role
in gene regulation, and thereby in protein expression, is
significant (Figure 1). Synthesized in the nucleus as pri-
mary miRNAs by the RNA polymerase III enzyme
Figure 1 MicroRNA biogenesis. miRNA, microRNA; Pol II, polymerase II; RISC, RNA-induced silencing complex. Adapted from Goretti and
colleagues [81].
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called Drosha to generate precursor miRNAs, which are
exported to the cytoplasm to be finally cleaved by Dicer
to form mature miRNAs. Mature miRNAs bind to target
mRNA species and prevent their translation into pro-
teins, either by induction of mRNA degradation by
RNA-induced silencing complex when there is a perfect
match between miRNA sequence and target mRNA, or
by translational blockade when the two sequences are
mis-matched. In mammals, miRNAs predominantly regu-
late gene expression by induction of mRNA degradation
[37]. This property allows miRNAs to regulate developmen-
tal, physiological, as well as pathophysiological processes
[38]. In the heart, miRNAs have been shown to regulatemany functions, such as apoptosis, angiogenesis, contractil-
ity, and hypertrophy [39]. Similarly, miRNAs are abun-
dantly expressed in the brain [40], where they play key
roles in development, plasticity and disease evolution [41].
A PubMed literature search revealed a plethora of re-
search articles related to miRNAs during the past dec-
ade. More than 2,600 articles have been published to
date in the field of brain and neurological research
(Figure 2A). In the cardiovascular system, 2,300 articles
have been published on miRNAs since the first identifi-
cation of cardiac-enriched miRNAs by Lagos-Quintana
and colleagues in 2002 [42] (Figure 2B). Significantly for
biomarker research, circulating miRNAs are stable (that
is, protected from RNase degradation), and can be easily
Figure 2 PubMed literature searches of research articles related to microRNAs. (A) Evolution of the number of articles related to microRNAs
(miRNAs) in the neurological system. Literature search was performed in PubMed using the query: (microrna OR mirna OR “micro-rna”) AND (brain OR
neuron OR neurological OR cerebral). (B) Evolution of the number of articles related to miRNAs in the cardiovascular system. Literature search was
performed in PubMed using the query: (microrna OR mirna OR “micro-rna”) AND (heart OR cardiac OR myocardial OR cardiovascular).
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niques. A PubMed search (query (microrna OR mirna
OR “micro-rna”) AND (brain OR neuron OR neuro-
logical OR cerebral) AND (biomarker OR diagnostic OR
prognostic) showed that, to date, 624 articles were re-
lated to miRNAs as potential biomarkers of neurological
diseases, the vast majority of which address the value of
miRNAs as diagnostic biomarkers of brain tumors. With
respect to miRNAs as biomarkers of cardiovascular dis-
eases, we found 724 articles (query (microrna OR mirna
OR “micro-rna”) AND (heart OR cardiac OR myocardial
OR cardiovascular) AND (biomarker OR diagnostic OR
prognostic)), the larger part focusing on myocardial in-
farction (125 articles) and heart failure (106 articles).
Interestingly, only two reports focused on cardiac arrest
(Figure 3). Furthermore, the large part of these studiesaddressed the diagnostic value of miRNAs, not their
prognostic value.
Consequently, miRNAs have emerged as candidate
biomarkers of brain and heart diseases.
MicroRNAs and cardiac diseases
Several studies suggested that miRNAs may be used as
diagnostic biomarkers of cardiovascular diseases, notably
acute myocardial infarction (for recent reviews, see
[43-45]). Other reports have addressed the prognostic
value of circulating miRNAs after acute myocardial in-
farction [46-50]. We observed a significant inverse cor-
relation between miR-208b and miR-499 and the left
ventricular ejection fraction of patients 4 months after
acute myocardial infarction [51]. However, these two
miRNAs failed to accurately predict outcome in these
Figure 3 Numbers of articles related to microRNAs and their
biomarker value, according to cardiovascular disease type.
Literature search was performed in PubMed using the query:
(microrna OR mirna OR “micro-rna”) AND (biomarker OR diagnostic
OR prognostic) AND (name of the specific disease).
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horts of patients with acute myocardial infarction, we
found that plasma levels of miR-150, a non-prototypical
cardiac miRNA, measured in the first few days following
infarction significantly predicts left ventricular remodeling
at 4 months [52]. In addition, a combination of several
miRNAs, including miR-150, improved the predictive
value of brain natriuretic peptide after acute myocardial
infarction [53]. While several studies characterized the
prognostic value of miRNAs in other cardiovascular con-
ditions such as heart failure, this has not been rigorously
investigated in cardiac arrest patients.
MicroRNAs and brain injury
MicroRNAs in the ischemic brain
The role of miRNAs in regulating brain development,
plasticity and nervous system diseases, including cancer,
has been reviewed previously [40,41,54,55]. After cardiac
arrest, the brain, as well as other peripheral organs, is
subjected to oxygen and nutrient deprivation as a conse-
quence of cessation of blood flow. Expression of miR-
NAs in the brain is altered following cerebral ischemia
[56], and several candidate miRNAs have been identified.
In rodent models, miR-233 is up-regulated in ischemic
brain and controls the response to neuronal injury by
down-regulating the expression of glutamate receptors.
This protects neurons from calcium influx mediated by
extracellular glutamate accumulation that characterizes
the excitotoxicity phase of brain ischemia. A lack of miR-
223 leads to memory deficits and neuronal cell death after
stroke [57]. The miR-200 and miR-182 families are down-regulated in the brain of hibernating squirrels and inhib-
ition of their activities protects neuronal cells from oxygen
and glucose deprivation-induced death [58]. In a rat model
of global cerebral ischemia, miR-181c regulates microglial-
mediated neuronal apoptosis following ischemia/reperfu-
sion injury [59]. miR-181c directly targets the 3’ untrans-
lated region of TNF-α mRNA, inhibiting apoptosis
mediated by TNF-α from activated microglial cells [59].
These data suggest that miRNAs are functionally import-
ant mediators of neurological impairment in ischemic
brain. Thus, miRNAs may represent not only new bio-
markers for neurological prognosis but also novel candi-
dates for neuroprotective therapy targets that may be
investigated following cardiac arrest.
Neuroprotection and microRNAs
A few miRNAs have been identified in therapeutic strat-
egies aiming at protecting the ischemic brain. Valproic
acid, a histone deacetylase inhibitor that reduces neuro-
logical sequelae and improves motor activity following
stroke in rodents [60], regulates miR-331 expression in
ischemic neuronal cells [56]. Combined therapy with
bortezomib, a proteasome inhibitor approved for treat-
ment of patients with multiple myeloma [61], and tissue
plasminogen activator, which is neuroprotective after
stroke in aged rats, is associated with an increase of
miR-146a expression in cerebral endothelial cells [56,62].
However, whether these miRNAs are neuroprotective
per se remains to be demonstrated.
Mild induced hypothermia and microRNAs
Numerous experimental models and two randomized clin-
ical trials have suggested that mild induced hypothermia
improves neurological outcome in patients who remain
unconscious following out-of-hospital cardiac arrest. This
treatment is now standard care in many intensive care
units. However, the use of therapeutic hypothermia has
been recently challenged by the results of our TTM trial
(Target Temperature Management After Cardiac Arrest),
which showed that lowering body temperature to 33°C in
unconscious survivors of out-of-hospital cardiac arrest did
not confer protection compared with 36°C [35]. The puta-
tive mechanisms of neuroprotection have been extensively
explored in experimental models but there has been little
focus on the expression and function of miRNAs. Recent
studies have reported that hypothermia regulates miRNAs
expression. Truettner and colleagues [63] showed that
miRNAs are dysregulated in the brain of hypothermic rats.
Pilotte and colleagues [64] showed that hypothermia regu-
lates miRNA expression through enhanced processing of
pre-miRNAs by Dicer. The cold-responsive protein Rbm3,
a glycine-rich RNA-binding protein, is implicated in disin-
hibition of Dicer in this process [65]. In pigs subjected to
cardiogenic shock, mild induced hypothermia down-
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search is needed to determine whether miRNAs are key
players in the neuroprotective effects of cooling. If this
could be demonstrated, miRNAs would represent a
novel class of neuroprotective agents that would deserve
further testing.
MicroRNAs as therapeutic target
Several lines of evidence support the concept that miR-
NAs functionally involved in the response of the brain
to ischemic injury and miRNAs participating in the neu-
roprotective effects of hypothermia may be interesting
therapeutic targets, either to protect the brain from
neurological damage or to stimulate neurological repair
after cardiac arrest. This assumption is supported by re-
cent reports, including that of Selvamani and colleagues
[67] showing that antagomirs to Let7f or miR-1 are able
to extend the neuroprotection afforded by insulin-like
growth factor-1 in a rat model of cerebral ischemia. In
addition, locked nucleic acid anti-miR130a reduced in-
farct volume and promoted recovery after transient focal
cerebral ischemia in rats [68].
The finding that exosomes conveying miRNAs are able
to cross the blood-brain barrier [69] suggests that simple
intravenous injection of artificial exosomes may repre-
sent an effective way of delivering miRNAs to the ische-
mic brain. Therefore, miRNAs are promising therapeutic
targets that may be further tested, alone or in adjunction
with hypothermia, to improve neurological recovery of
patients with cardiac arrest.
MicroRNAs as prognostic biomarkers after cardiac arrest
The biomarker value of miRNAs after cerebral ischemia
has been suggested by the observation that specific miR-
NAs have been detected in the blood after ischemic stroke
in both animals [70] and humans [71]. In addition, some
of these miRNAs might be potential biomarkers of ische-
mic stroke [71-73]. As a first attempt to identify miRNAs
with prognostic value after cardiac arrest, we performed a
proof-of-concept study in which we compared the plasma
miRnome of 14 patients with favorable outcome and 14
patients with poor outcome after cardiac arrest [74]. Using
microarrays covering almost 700 miRNAs (miRBase re-
lease 12.0), we observed a miRNA biosignature linked to
outcome. Among miRNAs differentially expressed be-
tween patients with favorable outcome and patients with
poor outcome, miR-122 and miR-21 were significant
predictors of neurological outcome (areas under the
receiver-operating characteristic curve of 0.73 and 0.77, re-
spectively) and mortality (P < 0.05) at 6 months. We could
verify that miR-122 and miR-21 were reliably expressed by
neuronal cells, as also shown elsewhere [75,76], comforting
our working hypothesis that miRNAs originating from
dying neurons after cardiac arrest can be measured in thebloodstream. Consistent with this hypothesis was the
demonstration that exosomes, which carry miRNAs out-
side cells, are able to cross the blood-brain barrier [69]. In
addition, disruption of the blood-brain barrier has been
shown after cerebral ischemia, which may facilitate the re-
lease of neuron-derived miRNAs into the bloodstream
[77]. Sheinerman and colleagues [78] identified brain-
enriched miRNAs in the blood of patients with mild
cognitive impairment, an early stage of multiple neurode-
generative diseases. Thus, brain-derived miRNAs present
in the bloodstream after cardiac arrest may indicate
neurological damage. Since the extent of neurological
damage is a critical determinant of post-cardiac arrest re-
covery, it is expected that circulating miRNAs may have
an interesting prognostic value in this setting. A recent
study from our group showing that brain-enriched miR-
124 is associated with neurological outcome after cardiac
arrest confirmed this assumption [79]. In future studies,
the added value of this novel category of biomarkers over
existing tools will have to be determined. Also, the sensi-
tivity and specificity of miRNAs, as well as their usefulness
for early prediction, will have to outperform current elec-
trophysiological and neuroimaging tools. Finally, the
techniques used to quantify miRNAs, which are still
time-consuming, will have to be improved, both in terms
of reproducibility, rapidity, cost, and standardization.
Conclusion and future perspectives
The discovery of miRNAs as regulators of gene expres-
sion has generated considerable excitement amongst re-
searchers. A number of studies have been conducted
addressing their potential as diagnostic, prognostic or
therapeutic targets in cerebral and cardiovascular dis-
eases. The value of miRNAs as biomarkers in patients
resuscitated following cardiac arrest has, however, re-
ceived little attention to date. Pilot studies suggest that
miRNAs may be useful predictors of neurological out-
come and survival after cardiac arrest and adequately
powered studies should be undertaken to validate these
preliminary findings. Ideally, these studies will determine
the optimal time for blood sampling, evaluate the added
value of miRNAs over existing prognostic tools, and
consider multimarker strategies. Importantly, while it
has been shown that cardiac-enriched miRNAs are re-
leased very early after cardiac injury [51], the kinetics of
release of brain-derived miRNAs after cardiac arrest will
have to be accurately characterized. The following main
technical issues regarding the measurement of circulat-
ing levels of miRNAs will have to be considered: advan-
tages and drawbacks of assessing miRNAs in whole
blood versus plasma, and appropriate normalization pro-
cedure. Interestingly, miRNAs may function not only as
novel biomarkers but also as potential therapeutic tar-
gets following cardiac arrest [80].
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